<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00218439</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-17307-1</org_study_id>
    <secondary_id>K23DA017307-01</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00218439</nct_id>
  </id_info>
  <brief_title>Effect of Paroxetine on Smokers' Cardiovascular Response to Stress - 1</brief_title>
  <official_title>Smoking, Antidepressants, and Response to Mental Stress</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <brief_summary>
    <textblock>
      Smokers report that they often smoke cigarettes during stressful times. The combined effect
      of smoking and exposure to stress leads to exaggerated increases in blood pressure, heart
      rate and other measures of stress response. This combination may result in greater
      cardiovascular harm than either smoking or stress alone. The purpose of this study is to
      determine the effects of paroxetine on the response to stress after smoking.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Smokers report that they often smoke cigarettes during stressful times. Smoking and stress
      produce similar physiological responses such as increases in heart rate, blood pressure, and
      adrenaline levels. The combination of smoking and stress results in greater increases in
      these physiological responses compared to smoking or stress alone. Such increases are thought
      to be harmful to cardiovascular health. Additionally, smokers with exaggerated responses to
      stress may be more likely to relapse following a smoking cessation attempt. The purpose of
      this study is to assess the effects of paroxetine, a selective serotonin reuptake inhibitor
      (SSRI), on the cardiovascular response to stress after smoking.

      Participants in this double-blind, placebo-controlled study will receive 1 month of
      paroxetine and 1 month of placebo with the order of which is taken during the first month
      randomly assigned. Paroxetine will be administered at a daily dose of 10 mg for the first
      week and increased to a daily dose of 20 mg for the remainder of the study. After one month
      of medication, participants will abstain from smoking for one night and then undergo mental
      stress testing the following day. Immediately prior to the mental stress testing,
      participants will smoke a cigarette. Mental stressors will include speaking and math tasks.
      Physiological measures of stress (e.g., blood pressure, heart rate, and plasma catecholamine
      concentrations) and subjective measures of stress will be evaluated. Following the second
      month of medication, participants will again undergo the procedure for mental stress testing
      and evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic Blood Pressure Response to Stress</measure>
    <time_frame>After 4 weeks of paroxetine / placebo</time_frame>
    <description>Change in systolic blood pressure from Resting period to that observed during a speech delivered immediately after smoking a cigarette</description>
  </primary_outcome>
  <other_outcome>
    <measure>Diastolic Blood Pressure Response to Stress</measure>
    <time_frame>After 4 weeks of paroxetine / placebo</time_frame>
    <description>Change in diastolic blood pressure from Resting period to that observed during a speech delivered immediately after smoking a cigarette</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart Rate Response to Stress</measure>
    <time_frame>After 4 weeks of paroxetine / placebo</time_frame>
    <description>Change in heart rate from Resting period to that observed during a speech delivered immediately after smoking a cigarette</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Epinephrine Concentration Response to Stress</measure>
    <time_frame>After 4 weeks of paroxetine / placebo</time_frame>
    <description>Change in plasma epinephrine concentrations from Resting period to those observed during a speech delivered immediately after smoking a cigarette</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Norepinephrine Concentration Response to Stress</measure>
    <time_frame>After 4 weeks of paroxetine / placebo</time_frame>
    <description>Change in plasma norepinephrine concentrations from Resting period to those observed during a speech delivered immediately after smoking a cigarette</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active medication for 4 weeks followed by placebo for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo for 4 weeks followed by active for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine</intervention_name>
    <description>10 mg for 1 week followed by 20 mg for 3 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Smokes an average of at least 10 cigarettes per day during the year prior to
             enrollment

        Exclusion Criteria:

          -  Interested in quitting smoking within the 3 months following enrollment

          -  Current unstable medical condition

          -  Substance abuse within the year prior to enrollment

          -  Current use of any medications (e.g., psychoactive medications, antihypertensives)
             that, in the opinion of the investigators, might interfere with study measures or that
             would be expected to interact with paroxetine (e.g., CYP2D6 substrates)

          -  Smoking cessation therapy within the 3 months prior to enrollment

          -  Regular use of any form of tobacco other than cigarettes

          -  Significant psychiatric disorders as assessed by the PRIME-MD and verified by a
             clinician

          -  History of hypersensitivity to any selective serotonin reuptake inhibitor

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kotlyar</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota, MN</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>College of Pharmacy</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <results_first_submitted>October 29, 2013</results_first_submitted>
  <results_first_submitted_qc>April 28, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 23, 2014</results_first_posted>
  <last_update_submitted>July 28, 2015</last_update_submitted>
  <last_update_submitted_qc>July 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paroxetine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo (4 Weeks) Then Paroxetine (4 Weeks)</title>
          <description>Placebo once daily in first intervention period and Paroxetine 10 mg daily for 1 week then increased to 20 mg once daily for remainder of second intervention period</description>
        </group>
        <group group_id="P2">
          <title>Paroxetine (4 Weeks) the Placebo (4 Weeks)</title>
          <description>Paroxetine 10 mg daily for 1 week then increased to 20 mg once daily for remainder of first intervention period, placebo once daily in second intervention period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Includes subjects who completed both laboratory sessions (n=62). One additional subject completed both laboratory sessions but did not have usable measures in the primary outcomes (cardiovascular measures) and was excluded</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo First 4 Weeks, Then Paroxetine for 4 Weeks</title>
          <description>Placebo once daily in first intervention period and Paroxetine 10 mg daily for 1 week then increased to 20 mg once daily for remainder of second intervention period</description>
        </group>
        <group group_id="B2">
          <title>Paroxetine First 4 Weeks, Then Placebo for 4 Weeks</title>
          <description>Paroxetine 10 mg daily for 1 week then increased to 20 mg once daily for remainder of first intervention period, placebo once daily in second intervention period</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.4" spread="14.1"/>
                    <measurement group_id="B2" value="40.0" spread="11.0"/>
                    <measurement group_id="B3" value="40.2" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Systolic Blood Pressure Response to Stress</title>
        <description>Change in systolic blood pressure from Resting period to that observed during a speech delivered immediately after smoking a cigarette</description>
        <time_frame>After 4 weeks of paroxetine / placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>After 4 Weeks of Placebo</title>
            <description>Change in systolic blood pressure from Resting period to that observed during a speech delivered immediately after smoking a cigarette in those receiving 4 weeks of placebo</description>
          </group>
          <group group_id="O2">
            <title>After 4 Weeks of Paroxetine</title>
            <description>Change in systolic blood pressure from Resting period to that observed during a speech delivered immediately after smoking a cigarette in those receiving 4 weeks of paroxetine (1 week of 10 mg once daily followed by 3 weeks of 20 mg once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure Response to Stress</title>
          <description>Change in systolic blood pressure from Resting period to that observed during a speech delivered immediately after smoking a cigarette</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.85" spread="0.78"/>
                    <measurement group_id="O2" value="11.71" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Diastolic Blood Pressure Response to Stress</title>
        <description>Change in diastolic blood pressure from Resting period to that observed during a speech delivered immediately after smoking a cigarette</description>
        <time_frame>After 4 weeks of paroxetine / placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>After 4 Weeks of Placebo</title>
            <description>Change in diastolic blood pressure fom Resting period to that observed during a speech delivered immediately after smoking a cigarette in those receiving 4 weeks of placebo</description>
          </group>
          <group group_id="O2">
            <title>After 4 Weeks of Paroxetine</title>
            <description>Change in diastolic blood pressure from Resting period to that observed during a speech delivered immediately after smoking a cigarette in those receiving 4 weeks of paroxetine (1 week of 10 mg once daily followed by 3 weeks of 20 mg once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure Response to Stress</title>
          <description>Change in diastolic blood pressure from Resting period to that observed during a speech delivered immediately after smoking a cigarette</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.78" spread="0.49"/>
                    <measurement group_id="O2" value="8.07" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Heart Rate Response to Stress</title>
        <description>Change in heart rate from Resting period to that observed during a speech delivered immediately after smoking a cigarette</description>
        <time_frame>After 4 weeks of paroxetine / placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>After 4 Weeks of Placebo</title>
            <description>Change in heart rate from Resting period to that observed during a speech delivered immediately after smoking a cigarette in those receiving 4 weeks of placebo</description>
          </group>
          <group group_id="O2">
            <title>After 4 Weeks of Paroxetine</title>
            <description>Change in heart rate from Resting period to that observed during a speech delivered immediately after smoking a cigarette in those receiving 4 weeks of paroxetine (1 week of 10 mg once daily followed by 3 weeks of 20 mg once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate Response to Stress</title>
          <description>Change in heart rate from Resting period to that observed during a speech delivered immediately after smoking a cigarette</description>
          <units>beats/minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.39" spread="0.56"/>
                    <measurement group_id="O2" value="20.02" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Plasma Epinephrine Concentration Response to Stress</title>
        <description>Change in plasma epinephrine concentrations from Resting period to those observed during a speech delivered immediately after smoking a cigarette</description>
        <time_frame>After 4 weeks of paroxetine / placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>After 4 Weeks of Placebo</title>
            <description>Change in plasma epinephrine concentrations from Resting period to those observed during a speech delivered immediately after smoking a cigarette in those receiving 4 weeks of placebo</description>
          </group>
          <group group_id="O2">
            <title>After 4 Weeks of Paroxetine</title>
            <description>Change in plasma epinephrine concentrations from Resting period to those observed during a speech delivered immediately after smoking a cigarette in those receiving 4 weeks of paroxetine (1 week of 10 mg once daily followed by 3 weeks of 20 mg once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Epinephrine Concentration Response to Stress</title>
          <description>Change in plasma epinephrine concentrations from Resting period to those observed during a speech delivered immediately after smoking a cigarette</description>
          <units>pg / ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.98" spread="3.42"/>
                    <measurement group_id="O2" value="34.94" spread="3.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Plasma Norepinephrine Concentration Response to Stress</title>
        <description>Change in plasma norepinephrine concentrations from Resting period to those observed during a speech delivered immediately after smoking a cigarette</description>
        <time_frame>After 4 weeks of paroxetine / placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>After 4 Weeks of Placebo</title>
            <description>Change in plasma norepinephrine concentrations from Resting period to those observed during a speech delivered immediately after smoking a cigarette in those receiving 4 weeks of placebo</description>
          </group>
          <group group_id="O2">
            <title>After 4 Weeks of Paroxetine</title>
            <description>Change in plasma norepinephrine concentrations from Resting period to those observed during a speech delivered immediately after smoking a cigarette in those receiving 4 weeks of paroxetine (1 week of 10 mg once daily followed by 3 weeks of 20 mg once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Norepinephrine Concentration Response to Stress</title>
          <description>Change in plasma norepinephrine concentrations from Resting period to those observed during a speech delivered immediately after smoking a cigarette</description>
          <units>pg / ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.31" spread="18.32"/>
                    <measurement group_id="O2" value="63.37" spread="18.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.82</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data collected during treatment (i.e. 4 weeks of paroxetine or 4 weeks of placebo)</time_frame>
      <desc>Subjects were asked at each visit an open ended question if they've experienced any side effects</desc>
      <group_list>
        <group group_id="E1">
          <title>During 4 Weeks of Placebo</title>
          <description>Participants receive placebo daily for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>During 4 Weeks of Paroxetine</title>
          <description>Participants received paroxetine 10 mg once daily for 1 week followed by 20 mg once daily for 3 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointenstinal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>change in appetite</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>dry mouth / taste changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>unusual dreams</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>anxiety / irritability</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>sexual side effects</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Michael Kotlyar</name_or_title>
      <organization>University of Minnesota College of Pharmacy</organization>
      <phone>612-625-1160</phone>
      <email>kotly001@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

